02.05.2023 • NewsSolvayHydrogen PeroxidesPropylene Oxide

Solvay Supplies Hydrogen Peroxide Process for China Plant

Solvay has signed an agreement with Chinese company Guangxi Chlor-Alkali Chemical (GHCAC) to supply a technology license for its hydrogen peroxide technology.

The agreement will allow GHCAC to build a hydrogen peroxide plant at Qinzhou in the Guangxi Zhuang Autonomous Region, which will support the site’s production of 300,000 t/y propylene oxide, as well as other units.

Propylene oxide is used in the manufacture of a wide range of materials in many industrial and commercial market segments, including polyurethanes, propylene glycol ethers and propoxylated organic specialty compounds.

© Getty Images/iStockphoto
© Getty Images/iStockphoto

Under the deal, the Belgian chemicals company will provide a “comprehensive” process design packaging and operating expertise, among other services. It will also supply GHCAC with proprietary 2-amylanthraquinone (AQ), which Solvay said is the key chemical that contributes to the high productivity and environmental friendliness of its technology.

Furthermore, once the plant starts up (an onstream date was not disclosed), Solvay will take some of the hydrogen peroxide output to support the growth of its related business in China, particularly in the south of the country.

Author: Elaine Burridge, Freelance Journalist

Company

Logo:

Solvay

Rue du Prince Albert 33
1050 Bruxelles
Belgium

Company contact







Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.